The Multiple Myeloma Research Foundation’s CoMMpass study, a prospective, longitudinal observational study of 1,143 newly diagnosed, previously untreated multiple myeloma patients, revealed critical genetic markers that can better predict disease progression and identify patients at risk of transitioning to more aggressive forms of the disease.
A 12-year observational study which aimed to sequence the genome, exome, and RNA in tumors from patients with multiple myeloma was able to define distinct subtypes of the disease, according to an international team of scientists led by researchers from the Translational Genomics Research Institute, part of City of Hope.
Research from Children’s Medical Center Research Institute at UT Southwestern shows that metastatic kidney cancers rely heavily on mitochondrial metabolism. These findings are contrary to how tumors operate while still in the kidney.
A study led by researchers at UT Southwestern Medical Center reveals significant disparities across the country in the use of immunotherapy for patients with advanced kidney and bladder cancers.
Misetionamide, a tumor cell-selective small molecule drug that is broadly active in multiple cancer models, demonstrated excellent monotherapy results as well as synergistic activity with PARP inhibitors and bevacizumab antineoplastic in ovarian cancer in a recent preclinical study.
Esopredict, a test developed by Johns Hopkins Kimmel Cancer Center investigators, could give gastroenterologists insight into which patients with Barrett’s esophagus are likely to progress to esophageal cancer or an abnormal collection of cells called high-grade dysplasia, according to a recent study. This information could help physicians determine how to monitor or manage patients during clinical care.
A study recently published in BJUI Compass found that Unfold AI, an FDA-cleared artificial intelligence algorithm developed by Avenda Health, accurately predicted extracapsular extension risk (ECE) and outperformed conventional methodologies.
FDA approved Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
FDA approved durvalumab (Imfinzi) with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.
FDA accepted Bristol Myers Squibb’s supplemental Biologics License Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a potential first-line treatment for adult patients with unresectable hepatocellular carcinoma.
